Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium

详细信息    查看全文

• 作者：Palanivel Gajalakshmi ; Mani Krishna Priya ; Thangaraj Pradeep ; Jyotirmaya Behera ; Kandasamy Muthumani¹ ; Srinivasan Madhuwanti² ; Uttara Saran ; Suvro Chatterjee ; ^{soovro@yahoo.ca}
• 关键词：Nitric oxide ; Endothelium ; Tamoxifen citrate ; Capecitabine ; Epirubicin ; cGMP
• 刊名：Toxicology and Applied Pharmacology
• 出版年：2013
• 出版时间：1 June, 2013
• 年：2013
• 卷：269
• 期：2
• 页码：121-131
• 全文大小：1809 K

文摘

Widely used chemotherapeutic breast cancer drugs such as Tamoxifen citrate (TC), Capecitabine (CP) and Epirubicin (EP) are known to cause various cardiovascular side-effects among long term cancer survivors. Vascular modulation warrants nitric oxide (NO) signal transduction, which targets the vascular endothelium. We hypothesize that TC, CP and EP interference with the nitric oxide downstream signaling specifically, could lead to cardiovascular dysfunctions. The results demonstrate that while all three drugs attenuate NO and cyclic guanosine mono-phosphate (cGMP) production in endothelial cells, they caused elevated levels of NO in the plasma and RBC. However, PBMC and platelets did not show any significant changes under treatment. This implies that the drug effects are specific to the endothelium. Altered eNOS and phosphorylated eNOS (Ser-1177) localization patterns in endothelial cells were observed following drug treatments. Similarly, the expression of phosphorylated eNOS (Ser-1177) protein was decreased under the treatment of drugs. Altered actin polymerization was also observed following drug treatment, while addition of SpNO and 8Br-cGMP reversed this effect. Incubation with the drugs decreased endothelial cell migration whereas addition of YC-1, SC and 8Br-cGMP recovered the effect. Additionally molecular docking studies showed that all three drugs exhibited a strong binding affinity with the catalytic domain of human sGC. In conclusion, results indicate that TC, CP and EP cause endothelial dysfunctions via the NO-sGC-cGMP pathway and these effects could be recovered using pharmaceutical agonists of NO signaling pathway. Further, the study proposes a combination therapy of chemotherapeutic drugs and cGMP analogs, which would confer protection against chemotherapy mediated vascular dysfunctions in cancer patients.